NASDAQ:NERV

Minerva Neurosciences Stock Predictions

Healthcare > Biotechnology

Buy NERV

*Your capital is at risk

$4.75

-0.0900 (-1.86%)

At Close: Jun 02, 2026

Currently predicting for Thu, 4 Jun 2026

NERV Prediction Chart

NERV Predictions History

Latest community submissions for NERV.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
Rybkarybka Merchant	Oct 4, 2021	$1.90 -84.27%	$1.51	X	74.17%	0
alslaimy111.246443	Jul 2, 2021	$3.66 -80.28%	$2.32	X	42.24%	0
JS Pro	Jun 8, 2020	$3.69 -88.02%	$3.85	V	95.84%	1
Mitch27	Jun 8, 2020	Bearish	$3.85	V	—	1
JS Pro	Jun 1, 2020	$5.04 -85.04%	$4.21	X	80.29%	1
Michael Tyler Merchant @MichaelTyler.131297	Jun 1, 2020	$3.54 -89.49%	$4.21	V	84.09%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for NERV with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT MINERVA NEUROSCIENCES

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	18.86%	May 06
GLBE $31.61	5.35%	May 05
SAP $172.39	10.69%	May 05
W WCLD $27.34	27.18%	Apr 29
ADBE $243.57	7.61%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by